Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation

Inclusion Criteria:

1. Voluntarily sign the informed consent form, understand the trialprocedures, and bewilling to comply with all trial procedures andrestrictions;

2. 18 years to 45 years (inclusive), male and female;

3. Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Body mass index (BMI) : 18-26 kg/m2 (inclusive) ;

4. Normal lung function during the screening period, no airway obstruction, FEV1 andforced vital capacity(FVC) are at least 80% of the predicted values;

5. Never smoked or have quit smoking for ≥ 12 months and have a previous smokinghistory of < 5 pack per years;

6. Subjects are willing to voluntarily use effectivecontraceptives from screening to atleast 3 months after the last dose administration.

Exclusion Criteria:

1. Have a history of severe and uncontrolled diseases, such ascardiovascular,respiratory, liver, gastrointestinal, endocrine,hematologic, mental/nervous systemsdiseases within 3 months prior to screening;

2. Have a history of any malignant tumors;

3. Normal or abnormal vital signs, physical examination, laboratory examination,electrocardiogram, and imageological examination have no clinical significance;

4. Previous or current gastrointestinal, liver, kidney, or other disease known tointerfere with drug absorption, distribution, metabolism, or excretion;

5. Acute respiratory infections occurred within 6 weeks before screening and/or beforerandomization;

6. Have a history of high consumption of grapefruit juice, methylxanthinerich food orbeverage within 48 hours before the administration;

7. Average alcohol intake is more than 14 unit per week (1unit=10g alcohol , 1 unit=285mL 4.9% alcohol beer, or 30 mL 40% alcohol spirit, or 100mL 12% alcohol wine) withinthe 3 months prior to screening;

8. Have a history of drug abuse prior to screening, or positive urine drug screen atscreening;

9. Blood donation (or blood loss) ≥400 mL within 3 months prior to the screening;

10. Subjects who have a allergic to any component of HSK39004 or allergic history;

11. Subjects who use any live vaccine within 30 days prior to screening;

12. Have participated in any clinical investigator within 3 months prior to screening;

13. A pregnant/lactating woman, or has a positive pregnancy test at screening or duringthe trial;

14. Not suitable for this study as judged by the investigator.